How this supports a project
An mRNA-LNP project contains two connected specifications: the RNA construct and transcription inputs, and the identities, ratios, and quality attributes of the lipid formulation.
Keep RNA inputs and LNP composition separate
The RNA specification covers the coding sequence, untranslated regions, 5′ cap strategy, nucleotide composition, poly(A) design, and purification or analytical requirements. Cap analog choice and modified nucleoside triphosphates are part of the in vitro transcription plan, not lipid ingredients.
The delivery specification covers the lipid identities and their molar ratios. Common mRNA-LNP research formulations use an ionizable lipid, a phospholipid, cholesterol or another sterol, and a PEG-lipid, but component identity and ratio remain formulation-specific and must be tested as a complete system.
Typical material-planning workflow
Define the RNA construct
Record the coding region, 5′ and 3′ UTRs, transcription start, poly(A) design, and target RNA length.
Choose the cap route
Specify co-transcriptional or post-transcriptional capping, cap structure, initiating sequence requirements, and how capped RNA will be confirmed.
Set the nucleotide composition
Define the ATP, CTP, GTP, UTP, or modified NTP set rather than referring generically to modified mRNA.
Plan RNA purification and analysis
Define checks for identity, integrity, cap incorporation, poly(A), residual DNA, and double-stranded RNA byproducts as required for the research stage.
Define the lipid component set
Record the exact ionizable lipid, helper phospholipid, sterol, PEG-lipid, and molar ratio for each formulation candidate.
Formulate and characterize the LNP
Track formulation conditions and define particle-size, dispersity, encapsulation, RNA integrity, lipid identity, and stability measurements appropriate to the study.
What to define before an inquiry
RNA construct and transcription plan
Provide the construct map, promoter or initiating sequence constraints, cap route, poly(A) approach, and nucleotide set.
Modified NTP definition
Name each modified NTP and its intended replacement level; do not describe the input only as a modified nucleotide mix.
Lipid identities and molar ratios
Specify every formulation component and ratio because the ionizable lipid cannot be assessed in isolation from the other lipids.
Formulation conditions
Record mixing method, solvent and buffer system, flow or volume ratio, concentration, and downstream exchange conditions.
Analytical endpoints
Separate RNA quality attributes from particle attributes and define acceptance criteria for the research stage.
Application boundary
This page organizes RNA and lipid material choices for research planning. It does not provide a universal LNP formula, predict expression or biodistribution, or establish safety, clinical suitability, or regulatory status. Those outcomes depend on the complete construct, formulation, process, route, and experimental model.
Related catalog and technical pages
Sources
- 1.Novel cap analogs for in vitro synthesis of mRNAs with high translational efficiency (RNA, 2004)
- 2.Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA (Immunity, 2005)
- 3.A Novel Amino Lipid Series for mRNA Delivery (Molecular Therapy, 2018)
- 4.Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines (Molecular Therapy - Nucleic Acids, 2019)
- 5.Optimization of phospholipid chemistry for improved lipid nanoparticle delivery of messenger RNA (Journal of Controlled Release, 2022)